GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo.

Blood
Caroline PabstFrédéric Barabé

Abstract

Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy, which is initiated and driven by a rare fraction of leukemia stem cells (LSCs). Despite the difficulties of identifying a common LSC phenotype, there is increasing evidence that high expression of stem cell gene signatures is associated with poor clinical outcome. Identification of functionally distinct subpopulations in this disease is therefore crucial to dissecting the molecular machinery underlying LSC self-renewal. Here, we combined next-generation sequencing technology with in vivo assessment of LSC frequencies and identified the adhesion G protein-coupled receptor 56 (GPR56) as a novel and stable marker for human LSCs for the majority of AML samples. High GPR56 expression was significantly associated with high-risk genetic subgroups and poor outcome. Analysis of GPR56 in combination with CD34 expression revealed engraftment potential of GPR56(+)cells in both the CD34(-)and CD34(+)fractions, thus defining a novel LSC compartment independent of the CD34(+)CD38(-)LSC phenotype.

References

Dec 4, 2001·Nature Genetics·Scott A ArmstrongStanley J Korsmeyer
Mar 15, 2006·International Journal of Hematology·John E Dick, Tsvee Lapidot
Sep 26, 2006·Nature Medicine·Liqing JinJohn E Dick
Jun 20, 2007·Proceedings of the National Academy of Sciences of the United States of America·Naoki HosenIrving L Weissman
Dec 16, 2010·The Journal of Clinical Investigation·Jean-Emmanuel SarryMartin Carroll
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Max JanRavindra Majeti
Jun 3, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christoph RölligGerhard Ehninger
Aug 30, 2011·Nature Medicine·Kolja EppertJohn E Dick
Aug 31, 2012·Science Translational Medicine·Max JanRavindra Majeti
Feb 6, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Zejuan LiJianjun Chen
May 3, 2013·The New England Journal of Medicine·UNKNOWN Cancer Genome Atlas Research NetworkGreg Eley
Aug 19, 2014·Cell Stem Cell·Grant A ChallenMargaret A Goodell
Dec 31, 2014·The Journal of Experimental Medicine·Parham Solaimani KartalaeiElaine Dzierzak

❮ Previous
Next ❯

Citations

Feb 6, 2017·Blood·Daniel Thomas, Ravindra Majeti
Jun 27, 2017·Nature Cell Biology·Fengbiao ZhouCarsten Müller-Tidow
Mar 5, 2017·Cell Stem Cell·Guillaume Richard-Carpentier, Guy Sauvageau
Jul 1, 2017·Cancers·Tania Martiáñez CanalesLinda Smit
Jul 14, 2017·Cell Death & Disease·Hendrik FolkertsEdo Vellenga
Sep 7, 2017·Proceedings of the National Academy of Sciences of the United States of America·Gabriel S SalzmanDemet Araç
Mar 13, 2019·Basic & Clinical Pharmacology & Toxicology·Tobias Langenhan
Sep 30, 2017·Blood Cancer Journal·C K LaiR K Humphries
Apr 30, 2019·Current Medicinal Chemistry·Frode SelheimAnna M Aragay
Oct 28, 2019·Leukemia·Abdelrahman H ElsayedJatinder K Lamba
Jul 11, 2020·Expert Opinion on Drug Discovery·Andrey D BondarevHelgi B Schiöth
Aug 3, 2019·The Journal of Experimental Medicine·Gaëlle H MartinChristopher Y Park
Aug 6, 2020·Frontiers in Cell and Developmental Biology·Alicia VillatoroLorena Arranz
Apr 30, 2020·Genome Medicine·Jean-David LaroucheClaude Perreault
Jul 20, 2019·Blood·George S Vassiliou
Mar 30, 2018·Frontiers in Oncology·Nicole Scholz
Aug 24, 2018·Frontiers in Oncology·Kuan-Yeh Huang, Hsi-Hsien Lin
Feb 21, 2019·Blood Advances·Céline MoisonGuy Sauvageau
Sep 22, 2020·PloS One·Johan GustafssonJens Nielsen
Nov 5, 2020·Blood Advances·Jenny M HoJean C Y Wang
Jan 4, 2021·Stem Cell Research·Nikolaos Spyrou, Eirini P Papapetrou
Jan 30, 2021·Journal of Internal Medicine·L I Shlush, T Feldman
Feb 9, 2021·EMBO Molecular Medicine·Alexander C Lewis, Lev M Kats
Dec 17, 2020·Cancers·Marlon ArnoneClaudia Lengerke

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.